A surprising and unexpected finding with clear therapeutic potential was the evidence that reduction of SOD1 protein expression by Acthar is greatest in the spinal cord and brain stem of end-stage G93A mice which are the most clinically relevant regions of the CNS with respect to ALS, and to a lesser degree in other areas of the brain. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.